Foresite Capital Closes $900 Million Fund VI to Invest in Healthcare and Life Sciences

Foresite Capital, a renowned healthcare and life sciences investment firm, has successfully concluded its sixth fund, amassing a total of $900 million in capital commitments. The new fund will enable Foresite Capital to continue its pursuit of pioneering technologies, spanning from innovative therapeutics to companies operating at the intersection of technology and biotechnology.

Fund VI is set to focus on investing in companies within precision therapeutics, life science infrastructure, and healthcare delivery, with notable investments in Alumis, CG Oncology, Latigo, RayThera, and Xaira Therapeutics. The fund has garnered support from diverse investors, including university endowments, charitable foundations, medical institutions, pension funds, insurance companies, private banks, and family offices globally.

Foresite Capital, managing over $3.5 billion in assets, strives to support healthcare and life sciences ventures at various stages of their development, with a focus on addressing unmet medical needs. Headquartered in the San Francisco Bay Area, Foresite Capital also maintains a presence in Los Angeles and New York City.